Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 9/20 | 0.37 |
| ▸ | CA1 | P00915 | 7/20 | 0.37 |
| ▸ | MMP1 | P03956 | 3/20 | 0.35 |
| ▸ | MMP2 | P08253 | 3/20 | 0.35 |
| ▸ | MMP9 | P14780 | 3/20 | 0.35 |
| ▸ | MMP8 | P22894 | 3/20 | 0.35 |
| ▸ | MMP13 | P45452 | 3/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1618323 | 0.89 | CA2 (0.42) | EPHX1CA2CA1MMP1MMP2 | |
| SCHEMBL1618144 | 0.84 | CA2 (0.46) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL3573472 | 0.75 | EPHX1 (0.45) | EPHX1CA2CA1CA7CA13 | |
| SCHEMBL14066567 | 0.74 | CA1 (0.36) | EPHX1CA2CA1MMP1MMP2 | |
| SCHEMBL16946101 | 0.71 | EPHX1 (0.47) | EPHX1CA2CA1CA7CA13 | |
| SCHEMBL11173595 | 0.71 | EPHX1 (0.42) | EPHX1CA2CA1CA7CA13 | |
| SCHEMBL12789664 | 0.69 | EPHX1 (0.60) | EPHX1CA2CA1CA7CA13 | |
| SCHEMBL6305655 | 0.68 | EPHX1 (0.44) | EPHX1CA2CA1CA7CA13 | |
| SCHEMBL2491671 | 0.67 | CA1 (0.59) | EPHX1CA2CA1CA7 | |
| SCHEMBL396162 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3908573-B1 | ASYMMETRIC ELECTROLYTE SALTS AND BATTERIES INCORPORATING SUCH SALTS | OHIO STATE INNOVATION FOUNDATION (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12021195-B2 | Asymmetric electrolyte salts and batteries incorporating such salts | OHIO STATE INNOVATION FOUNDATION (US) | 2024-06-25 | — | — | US | disclosed |
| US-20220102759-A1 | ASYMMETRIC ELECTROLYTE SALTS AND BATTERIES INCORPORATING SUCH SALTS | OHIO STATE INNOVATION FOUNDATION (US) | 2022-03-31 | — | — | US | disclosed |
| EP-1414088-B1 | NOVEL ONIUM SALT, ELECTROLYTE FOR NONAQUEOUS CELL CONTAINING THE NOVEL ONIUM SALT FOR NONAQUEOUS CELL, AND METHOD FOR OPTIMIZING A NEGATIVE ELECTRODE USING AN ELECTROLYTE CONTAINING THE ONIUM SALT | TOKUYAMA CORP (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-7923142-B2 | Onium salt, electrolyte for nonaqueous cell containing the novel onium salt for nonaqueous cell and method for optimizing negative electrode using electrolyte containing onium salt | TOKUYAMA CORPORATION (JP) | 2011-04-12 | — | — | US | disclosed |
| US-7846576-B2 | Onium salt, electrolyte for non-aqueous cell containing the novel onium salt for nonaqueous cell, and method for optimizing negative electrode using elecrolyte containing onium salt | TOKUYAMA CORPORATION (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20080039634-A1 | NOVEL ONIUM SALT, ELECTROLYTE FOR NONAQUEOUS CELL CONTAINING THE NOVEL ONIUM SALT FOR NONAQUEOUS CELL AND METHOD FOR OPTIMIZING NEGATIVE ELECTRODE USING ELECTROLYTE CONTAINING ONIUM SALT | TOKUYAMA CORPORATION | 2008-02-14 | — | — | US | disclosed |
| US-20040170890-A1 | Novel onium salt, electrolyte for non-aqueous cell containing the novel onium salt for nonaqueous cell, and method for optimizing negative electrode using elecrolyte containing onium salt | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2004-09-02 | — | — | US | disclosed |
| EP-1414088-A1 | NOVEL ONIUM SALT, ELECTROLYTE FOR NONAQUEOUS CELL CONTAINING THE NOVEL ONIUM SALT FOR NONAQUEOUS CELL, AND METHOD FOR OPTIMIZING NEGATIVE ELECTRODE USING ELECTROLYTE CONTAINING ONIUM SALT | Tokuyama Corporation (JP) | 2004-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040170890-A1 | Novel onium salt, electrolyte for non-aqueous cell containing the novel onium salt for nonaqueous cell, and method for optimizing negative electrode using elecrolyte containing onium salt | ALPL, CACNA2D3, FASTKD5 | EPHX1 2757/4885CA2 4/4885CA1 9/4885 |
| US-12021195-B2 | Asymmetric electrolyte salts and batteries incorporating such salts | HCN2, KCNN2, POTEE | EPHX1 2751/4885CA2 163/4885CA1 168/4885 |
| US-20080039634-A1 | NOVEL ONIUM SALT, ELECTROLYTE FOR NONAQUEOUS CELL CONTAINING THE NOVEL ONIUM SALT FOR NONAQUEOUS CELL AND METHOD FOR OPTIMIZING NEGATIVE ELECTRODE USING ELECTROLYTE CONTAINING ONIUM SALT | CA2, SLC9A2, HCN3 | EPHX1 4476/4885CA2 1/4885CA1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.